Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Long-Term Debt Repayments (2016 - 2018)

Amicus Therapeutics' Long-Term Debt Repayments history spans 8 years, with the latest figure at -$218000.0 for Q4 2018.

  • For the quarter ending Q4 2018, Long-Term Debt Repayments fell 327.08% year-over-year to -$218000.0, compared with a TTM value of -$218000.0 through Dec 2021, down 53.52%, and an annual FY2023 reading of $408.0 million, changed N/A over the prior year.
  • Long-Term Debt Repayments for Q4 2018 was -$218000.0 at Amicus Therapeutics, down from $76000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $5.6 million in Q1 2014, with the low at -$218000.0 in Q4 2018.
  • Average Long-Term Debt Repayments over 4 years is $549181.8, with a median of $71000.0 recorded in 2016.
  • Year-over-year, Long-Term Debt Repayments rose 28.0% in 2017 and then crashed 327.08% in 2018.
  • Tracing FOLD's Long-Term Debt Repayments over 4 years: stood at $5.6 million in 2014, then tumbled by 98.66% to $75000.0 in 2016, then rose by 28.0% to $96000.0 in 2017, then tumbled by 327.08% to -$218000.0 in 2018.
  • Per Business Quant, the three most recent readings for FOLD's Long-Term Debt Repayments are -$218000.0 (Q4 2018), $76000.0 (Q3 2018), and $71000.0 (Q2 2018).